Tracleer(R) (bosentan) Receives EU Approval For Treatment Of … - Medical News Today (press release) (Primary Pulmonary Hypertension News)
Tracleer(R) (bosentan) Receives EU Approval For Treatment Of …
Medical News Today (press release), UK - The primary endpoints for the EARLY trial were changes in pulmonary vascular resistance (PVR) and exercise capacity as measured by a 6-minute walk test … Tracleer® (bosentan) receives EU approval for treatment of … |
Health Happenings
Fort Worth Star Telegram, TX - COPD (chronic obstructive pulmonary disease) Support Group, for pulmonary patients and their families, meets at 1:30 pm the first Tuesday of the month at … |
A National Study of Chronic Disease Prevalence and Access to Care …
Annals of Internal Medicine - … hypertension, diabetes, hypercholesterolemia, active asthma or chronic obstructive pulmonary disease, previous cancer, and measures of access to care. … |
One-Third of Uninsured Are Chronically Ill
U.S. News & World Report, DC - Other conditions examined were asthma, high cholesterol, chronic obstructive pulmonary disease or a previous diagnosis of cancer. … |
Planned R&D Hike Gives Gilead Investors Pause
TMCnet - The company also is pushing forward with cicletanine, a once-daily oral agent in pulmonary arterial hypertension (PAH) and recently started a Phase IV trial … |
